SAGE Therapeutics, Inc.
(NASDAQ : SAGE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Loading SAGE News...
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
1.56%16.6110.2%$221.79m
SHPGShire PLC Sponsored ADR
2.05%184.710.3%$192.76m
PRGOPerrigo Co. Plc
0.06%84.144.3%$133.97m
MNKMallinckrodt Plc
-0.72%53.8211.1%$109.76m
MDCOMedicines Company
-1.23%51.5819.0%$98.68m
ENDPEndo International Plc
4.54%13.489.0%$97.37m
PRXLPAREXEL International Corporation
-0.15%65.847.5%$84.88m
UTHRUnited Therapeutics Corporation
-2.38%143.4813.5%$80.75m
JAZZJazz Pharmaceuticals Plc
0.32%135.382.3%$69.33m
ICPTIntercept Pharmaceuticals, Inc.
-8.01%112.9621.9%$60.63m
SAGESAGE Therapeutics, Inc.
-0.67%61.5212.1%$48.52m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-1.40%123.4210.9%$47.41m
PTLAPortola Pharmaceuticals, Inc.
-2.58%31.318.8%$39.59m
HZNPHorizon Pharma plc
0.12%17.0611.1%$38.87m
SGYPSynergy Pharmaceuticals, Inc.
-5.69%5.3316.1%$38.44m

Company Profile

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company engages in the development and commercialization of novel medicines to treat central nervous system disorders. Its product candidate includes SAGE-547, which is in clinical development for super-refractory status epileptics; SAGE-217; and SAGE-689, which are in IND-enabling toxicology and safety pharmacology testing. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.